Amikacin (Arikayce)

Status:: Red
Decision Date:: March 2021

Comments

RED

NICE ES36: Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial lung infections caused by Mycobacterium aviumcomplex in adults with limited treatment options who do not have cystic fibrosis. (Decision date - June 2021)